Category Research

Owkin, an AI-Biotech Unicorn, Expands to Germany, Austria, and Switzerland to Accelerate Research with Cutting-Edge AI

Owkin, the first end-to-end AI-biotech unicorn specializing in AI-driven precision drug discovery, development, and diagnostics, has announced its expansion into the DACH region (Germany, Austria, and Switzerland). This follows partnerships with nine top centers in the region, including Charité –…

Read MoreOwkin, an AI-Biotech Unicorn, Expands to Germany, Austria, and Switzerland to Accelerate Research with Cutting-Edge AI

Owkin, Leading AI-Biotech Innovator, Expands Cutting-Edge AI to Germany, Austria, and Switzerland to Advance Research

Owkin, the pioneering AI-biotech unicorn specializing in AI-driven precision drug discovery, development, and diagnostics, has launched its expansion into the DACH region (Germany, Austria, and Switzerland). This expansion follows strategic partnerships with nine leading institutions in the region, including Charité…

Read MoreOwkin, Leading AI-Biotech Innovator, Expands Cutting-Edge AI to Germany, Austria, and Switzerland to Advance Research

LEQEMBI® (Lecanemab) Launches in China for Alzheimer’s Disease Treatment

Biogen, headquartered in Cambridge, Massachusetts, and led by CEO Christopher A. Viehbacher, announced today the launch of “LEQEMBI®” (known as “乐意保®” in China), a humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody, in China. Approved in January 2024 for treating mild…

Read MoreLEQEMBI® (Lecanemab) Launches in China for Alzheimer’s Disease Treatment

Pfizer and BioNTech Granted Favorable CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union

Today, Pfizer and BioNTech announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of their Omicron JN.1-adapted monovalent COVID-19 vaccine, COMIRNATY® JN.1, for active immunization against COVID-19 caused…

Read MorePfizer and BioNTech Granted Favorable CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union

Augustine Therapeutics Secures EUR 17 Million in Series A Funding to Propel Lead Candidate into Clinical Development for Neurological Diseases

Augustine Therapeutics, a pioneering biotech firm dedicated to advancing treatments for neurodegenerative and cardiometabolic diseases, has successfully closed its Series A funding round with EUR 17 million (USD 18.5 million). Asabys Partners led the financing, joined by Eli Lilly and…

Read MoreAugustine Therapeutics Secures EUR 17 Million in Series A Funding to Propel Lead Candidate into Clinical Development for Neurological Diseases

BioStrand and PGxAI Partner to Develop AI Model for Pharmacogenomics with LENSai

ImmunoPrecise Antibodies Ltd. (IPA), an AI-driven biotherapeutic research and technology company, announced a strategic collaboration between its subsidiary, BioStrand, and PGxAI. This partnership aims to leverage BioStrand’s patented LENSai Foundation AI Model to advance pharmacogenomics, the study of how genetic…

Read MoreBioStrand and PGxAI Partner to Develop AI Model for Pharmacogenomics with LENSai

New Thermo Scientific Heracell Incubators Propel the Future of Fully Automated Labs

To advance workflow automation in cell therapy production, Thermo Fisher Scientific has launched the Thermo Scientific™ Heracell™ VIOS™ 250i AxD CO2 Incubators. These pioneering CO2 incubators are tailored for integration into automated and modular labs. Known for optimal cell growth…

Read MoreNew Thermo Scientific Heracell Incubators Propel the Future of Fully Automated Labs

MAIA Biotech’s Latest Advancements: Yearly Success and Breakthroughs in Cancer Treatment

MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, has announced its highlights and key achievements for the year so far, along with recent clinical progress regarding its lead candidate, THIO. THIO…

Read MoreMAIA Biotech’s Latest Advancements: Yearly Success and Breakthroughs in Cancer Treatment

Dr. Michael Donovan to Lead Personalized Cancer Therapy at Cellworks’ New CLIA Lab

A leader in Personalized Therapy Decision Support and Precision Drug Development, Cellworks, has announced the opening of a CLIA-certified computational laboratory in Franklin, Tennessee. Administered by the Centers for Medicare and Medicaid Services, CLIA (Clinical Laboratory Improvement Amendments) ensures high…

Read MoreDr. Michael Donovan to Lead Personalized Cancer Therapy at Cellworks’ New CLIA Lab